Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 2/20 | 0.33 |
| ▸ | CYCS | P99999 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181954 | 0.85 | STAT3 (0.41) | — | |
| SCHEMBL7589352 | 0.83 | TERT (0.40) | TERTENPP2TOP1CYCS | |
| SCHEMBL30417810 | 0.82 | TERT (0.40) | TERTENPP2TOP1CYCS | |
| Hydrochloric Acid SCHEMBL8183377 | 0.82 | TERT (0.40) | TERTENPP2TOP1CYCS | |
| SCHEMBL3089988 | 0.81 | TERT (0.41) | TERTENPP2TOP1CYCS | |
| SCHEMBL15006299 | 0.80 | ENPP2 (0.34) | TERTENPP2TOP1CYCS | |
| SCHEMBL30417440 | 0.80 | TERT (0.39) | TERTENPP2TOP1CYCS | |
| Hydrochloric Acid SCHEMBL8187817 | 0.80 | TERT (0.40) | TERTENPP2TOP1CYCS | |
| Hydrochloric Acid SCHEMBL4134394 | 0.80 | TERT (0.40) | TERTENPP2TOP1CYCS | |
| SCHEMBL3087029 | 0.78 | TERT (0.37) | TERTENPP2TOP1CYCS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140300857-A1 | OPHTHALMIC FILTER | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQU E) (FR) | 2014-10-09 | — | — | US | claimed |
| WO-2013084177-A1 | OPHTHALMIC FILTER | Essilor International (Compagnie Générale d'Optique) (FR) | 2013-06-13 | — | — | WO | claimed |
| EP-2602654-A1 | Ophthalmic filter | Essilor International (Compagnie Générale D'Optique) (FR) | 2013-06-12 | — | — | EP | claimed |
| US-20070248534-A1 | Auger effect-based cancer therapy method | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2007-10-25 | — | — | US | claimed |
| US-7008937-B2 | Porphyrins and metalloporphyrins for inhibiting heme iron uptake | FRONTIER SCIENTIFIC, INC. (US) | 2006-03-07 | — | — | US | claimed |
| US-20050112058-A1 | Auger effect-based cancer therapy method | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2005-05-26 | — | — | US | claimed |
| US-20040254155-A1 | Porphyrins and metalloporphyrins for inhibiting heme iron uptake | FRONTIER SCIENTIFIC, INC. | 2004-12-16 | — | — | US | claimed |
| US-12019316-B2 | Color-balanced lenses exhibiting reduced blue light transmittance | ESSILOR INTERNATIONAL (FR) | 2024-06-25 | — | — | US | disclosed |
| EP-3296799-B1 | OPTICAL ARTICLE WITH BLUE CUT, HIGH UV CUT AND HIGH CLARITY | ESSILOR INT (FR) | 2024-05-22 | — | — | EP | disclosed |
| EP-2602655-B1 | Ophthalmic filter | ESSILOR INT (FR) | 2024-04-03 | — | — | EP | disclosed |
| US-11635547-B2 | Composition for the manufacture of an ophthalmic lens comprising an encapsulated light-absorbing additive | ESSILOR INTERNATIONAL (FR) | 2023-04-25 | — | — | US | disclosed |
| EP-2602654-B1 | Ophthalmic filter | ESSILOR INT (FR) | 2023-04-19 | — | — | EP | disclosed |
| EP-3497488-B2 | OPHTALMIC LENS COMPRISING AN ENCAPSULATED LIGHT-ABSORBING ADDITIVE | ESSILOR INT (FR) | 2023-03-22 | — | — | EP | disclosed |
| US-7008937-B2 | Porphyrins and metalloporphyrins for inhibiting heme iron uptake | FRONTIER SCIENTIFIC, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050112058-A1 | Auger effect-based cancer therapy method | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2005-05-26 | — | — | US | disclosed |
| US-20040254155-A1 | Porphyrins and metalloporphyrins for inhibiting heme iron uptake | FRONTIER SCIENTIFIC, INC. | 2004-12-16 | — | — | US | disclosed |
| US-6451531-B1 | A FIRST BIOLOGICAL MOIETY SELECTED FROM THE GROUP CONSISTING OF A NUCLEIC ACID, A PEPTIDE NUCLEIC ACID, A PROTEIN, A STEROID AND A CARBOHYDRATE, SAID BIOLOGICAL MOIETY BEARING A 1,2-DIOXETANE PRECURSOR BOUND THERETO, SUCH THAT, UPON | TROPIX, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020106687-A1 | Dioxetane labeled probes and detection assays employing the same | APPLIED BIOSYSTEMS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6063574-A | Dioxetane labeled probes and detection assays employing the same | TROPIX, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-5800999-A | Dioxetane-precursor-labeled probes and detection assays employing the same | TROPIX, INC. (US) | 1998-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020106687-A1 | Dioxetane labeled probes and detection assays employing the same | DCLRE1A, DDB1, CYP4X1 | TERT 3807/4885ENPP2 3575/4885TOP1 46/4885 |
| US-20050112058-A1 | Auger effect-based cancer therapy method | LIG4, DNMT1, UNG | TERT 1097/4885ENPP2 4691/4885TOP1 36/4885 |
| US-20070248534-A1 | Auger effect-based cancer therapy method | LIG4, DNMT1, UNG | TERT 1097/4885ENPP2 4691/4885TOP1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.